drugset / Trial / NCT04805710
Rivaroxaban or Aspirin in Patients With CHD & GD Undergoing PCI
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of this study is to assess the efficacy and safety of rivaroxaban or aspirin combined with clopidogrel in patients with coronary heart disease and gastrointestinal diseases undergoing PCI.
Timeline
- Start
- 2021-03-17
- Primary completion
- 2022-09-16
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivaroxaban | Other / unclassified | 10 mg | — |
| Background | Clopidogrel | Small molecule | 75 mg | — |
Indications
No indication recorded.